Stock · NSE
GLAND
2,911.50▲ 37.10 (1.29%)Last 2 days · 15m candles9/10/2026, 02:53:25
Open: 2,906.50High: 2,915.20Low: 2,871.80Prev: 2,874.40
VERIFIEDMint Markets·9d★ ON YOUR LIST
Top 5 Sumeet Bagadia's breakout stocks: Gland Pharma, Astra Micro, Meesho, Westlife, Ujjivan | Target price, stop-lossAI summary· NEUTRAL
- ·Sumeet Bagadia identified Gland Pharma, Astra Micro, Meesho, Westlife, and Ujjivan as breakout stocks.
- ·He also noted that buying in Adani Enterprises, Adani Ports, Kotak Bank, Dr. Reddy's, Sun Pharma, and Infosys contributed to a market recovery.
- ·The article mentions target prices and stop-losses for the identified stocks.
VERIFIEDEconomic Times News·19d★ ON YOUR LIST
Gland Pharma and CAMS among 5 smallcap stocks sold by mutual funds in AugustAI summary· NEUTRAL
- ·Mutual funds sold shares of Gland Pharma in August.
- ·LIC Housing Finance was among the smallcap stocks sold by mutual funds.
- ·Gujarat Energy, CAMS, and Amber Enterprises India also saw significant mutual fund selling.
VERIFIEDET Markets·34d★ ON YOUR LIST
Gland Pharma block deal: Fosun Pharma divests 99 lakh shares worth Rs 2,800 croreAI summary· NEUTRAL
- ·Fosun Pharma divested a 6% stake in Gland Pharma for ₹2,800 crore through a block deal.
- ·The sale reduced Fosun Pharma's holding in Gland Pharma to 45.77%.
- ·Kotak, Axis, and ICICI Prudential Mutual Funds were among the major buyers in the deal.
VERIFIEDET Stocks·34d★ ON YOUR LIST
Large trade alert! Gland Pharma shares fall 3% after 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerAI summary· NEUTRAL
- ·Gland Pharma shares declined by 3% following two block deals involving 1.22 crore shares valued at approximately Rs 5,818 crore.
- ·Promoter Fosun Pharma Industrial was reportedly considering selling a 5% stake for Rs 2,279.5 crore.
- ·A recent USFDA inspection of two Gland Pharma facilities in Visakhapatnam resulted in zero Form 483 observations.
VERIFIEDET Stocks·34d★ ON YOUR LIST
Block deal alert! Gland Pharma shares in focus as promoter Fosun to sell 5% stake for Rs 2,279 croreAI summary· NEUTRAL
- ·Fosun Pharma Industrial is selling a 5% stake in Gland Pharma via a block deal at a floor price of Rs 2,763 per share.
- ·The block deal aims to raise Rs 2,279 crore.
- ·Gland Pharma recently reported strong Q1FY27 results and received zero Form 483 observations from the USFDA.
VERIFIEDET Markets·34d★ ON YOUR LIST
Block deal alert! Gland Pharma shares fall 3% as 1.2 crore shares change hands in 2 block deals; promoter Fosun likely sellerAI summary· NEUTRAL
- ·Gland Pharma shares declined by 3% following a block deal where 1.2 crore shares were traded.
- ·The company's VSEZ facility concluded a USFDA inspection with zero observations.
- ·Gland Pharma announced strong Q1FY27 results, reporting increased profit and revenue with substantial growth in its CDMO and B2B segments.
VERIFIEDET Markets·35d★ ON YOUR LIST
Stocks in news: HDFC Bank, M&M, Gland Pharma, CreditAccess Grameen and Bharat ForgeAI summary· NEUTRAL
- ·Nifty 50 fell 0.17% and Sensex declined 0.55% on Thursday.
- ·HDFC Bank raised nearly $12 billion through Foreign Currency Non-Resident deposits.
- ·Mahindra & Mahindra expects truck business integration by January and electric bus launch by April.
Google News, India stocks·35d★ ON YOUR LIST
Stocks to Watch Today: Gland Pharma, Rail Vikas Nigam, Cipla, Avalon Tech, Ramco Systems, ESDS Software,... - Moneycontrol.comVERIFIEDET Stocks·35d★ ON YOUR LIST
Gland Pharma shares: Promoter Fosun Pharma likely to divest 5% equity worth Rs 2,279 crore via block dealAI summary· NEUTRAL
- ·Fosun Pharma plans to sell 5% equity in Gland Pharma for Rs 2,279.5 crore.
- ·The divestment will occur via a block deal at Rs 2,763 per share.
- ·Gland Pharma reported a 47% rise in Q1FY27 profit.
VERIFIEDET Finance·55d★ ON YOUR LIST
Gland Pharma appoints Dr Reddy’s senior executive Deepak Sapra as CEOAI summary· NEUTRAL
- ·Gland Pharma has appointed Deepak Sapra as its new chief executive officer.
- ·Sapra's tenure is set to begin on November 16, 2026, pending his acceptance.
- ·He brings 27 years of executive experience, with over 23 years in pharmaceuticals, and currently leads API and Services at Dr Reddy’s Laboratories.
VERIFIEDET Stocks·58d★ ON YOUR LIST
Stocks to buy in 2026 for long term: Gland Pharma, Star Cement among 5 stocks that could give 10-30% returnAI summary· POSITIVE
- ·Gland Pharma and Star Cement are among five stocks identified for potential long-term investment.
- ·These stocks are projected to deliver returns ranging from 10% to 30%.
- ·The recommendations are sourced from top brokerage firms and ETNow.
VERIFIEDET Markets·58d★ ON YOUR LIST
Stocks to buy in 2026 for long term: Gland Pharma, Star Cement among 5 stocks that could give 10-30% returnAI summary· POSITIVE
- ·Gland Pharma and Star Cement are among five stocks identified for potential long-term investment.
- ·These stocks are projected to deliver returns ranging from 10% to 30%.
- ·The recommendations are sourced from top brokerage firms and ETNow.
Google News, NIFTY/SENSEX·58d★ ON YOUR LIST
Naukri, Gland Pharma, Bosch among buzzing stocks as SENSEX falls over 400 pts, NIFTY trades below 24,500 - UpstoxGoogle News, India stocks·58d★ ON YOUR LIST
Sensex Today | Stock Market LIVE Updates: Nifty below 24,500, Sensex down 360 pts; Gland Pharma, BSE, Lumax Auto most active - Moneycontrol.comVERIFIEDET Stocks·58d★ ON YOUR LIST
Gland Pharma shares rally 12% after Q1FY27 profit jumps 47% YoY. Should you buy, sell or hold?AI summary· POSITIVE
- ·Gland Pharma's Q1FY27 profit increased by 47% year-on-year.
- ·Revenue for Gland Pharma grew by 20% year-on-year in Q1FY27.
- ·Elara Securities raised earnings estimates but downgraded the stock to ‘Accumulate’ due to a 40% rally in three months.
Google News, NIFTY/SENSEX·59d★ ON YOUR LIST
Sensex Today | Stock Market LIVE Updates: Gland Pharma in focus after Jefferies, Goldman Sachs raise target - CNBC TV18VERIFIEDMint Markets·59d★ ON YOUR LIST
Gland Pharma Q1 Results: Net profit jumps 47% YoY to ₹317 crore; CDMO revenue rises 20%AI summary· POSITIVE
- ·Gland Pharma reported a 47% year-on-year increase in net profit for Q1 FY27, reaching ₹317 crore.
- ·The company's revenue grew 20% year-on-year to ₹1,800 crore.
- ·Revenue growth was primarily fueled by the CDMO and B2B segments, with significant contributions from the US and European markets.
VERIFIEDET Finance·60d★ ON YOUR LIST
Gland Pharma inks strategic CDMO deal with global pharma firm, eyes $90-100 million annual revenueAI summary· POSITIVE
- ·Gland Pharma has signed a strategic Manufacturing and Supply Agreement with a global pharmaceutical company for sterile injectable products.
- ·The deal encompasses 55 SKUs across three manufacturing sites.
- ·The agreement has an annualised revenue potential of $90-100 million, with revenue generation expected to commence in 2029.
VERIFIEDET Stocks·70d★ ON YOUR LIST
PCBL Chemical among 4 stocks closing above VWAP, signalling bullish shiftAI summary· POSITIVE
- ·PCBL Chemical, Blue Jet Healthcare, Gland Pharma, and International Gemological Institute closed above their VWAP on July 29.
- ·This indicates a potential bullish shift for these four Nifty500 stocks.
- ·The closing prices exceeded their daily volume-weighted average trading levels.
VERIFIEDMint Markets·71d★ ON YOUR LIST
Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — 30 July 2026AI summary· NEUTRAL
- ·Sumeet Bagadia recommends five breakout stocks to buy.
- ·The recommended stocks are Gland Pharma, PG Electroplast, Morepen Laboratories, Allied Blenders & Distillers, and Hexaware Technologies.
- ·The recommendations were made on 30 July 2026.
VERIFIEDET Finance·71d★ ON YOUR LIST
Gland Pharma gets USFDA nod for generic sugammadex injectionAI summary· NEUTRAL
- ·Gland Pharma has received USFDA approval for its generic sugammadex injection.
- ·The approval is for two specific strengths of the single-dose vial product.
- ·This generic sugammadex injection is bioequivalent to Merck's BRIDION injection.
Google News, NIFTY/SENSEX·78d★ ON YOUR LIST
Gland Pharma, Lupin, Dr Reddy's: All Nifty Pharma Stocks In Red After Trump's Drug Tariff Plan - NDTV ProfitVERIFIEDMint Markets·78d★ ON YOUR LIST
Lupin, Sun Pharma to Cipla: Pharma stocks decline after Trump’s tariffs plan on generic medicines importAI summary· NEGATIVE
- ·Several Indian pharmaceutical companies experienced a decline in their stock prices.
- ·Aurobindo Pharma, Ajanta Pharma, Lupin, Gland Pharma, and Zydus Lifesciences were among the top decliners.
- ·The decline occurred following a plan by Donald Trump regarding tariffs on generic medicine imports.
VERIFIEDET Markets·119d★ ON YOUR LIST
Honasa Consumer, 6 other stocks hit 52-week highs, rally up to 35% in a monthAI summary· POSITIVE
- ·Seven BSE 500 stocks, including Honasa Consumer, Aegis Logistics, and Gland Pharma, reached new 52-week highs.
- ·These stocks experienced gains of up to 35% in the past month.
- ·The rally occurred despite weakness in the broader market, driven by strong investor buying.
VERIFIEDET Stocks·119d★ ON YOUR LIST
Honasa Consumer, 6 other stocks hit 52-week highs, rally up to 35% in a monthAI summary· POSITIVE
- ·Seven BSE 500 stocks, including Honasa Consumer, Aegis Logistics, and Gland Pharma, reached new 52-week highs.
- ·These stocks experienced gains of up to 35% in the last month.
- ·The rally occurred despite weakness in the broader market, driven by strong investor buying.
VERIFIEDMint Markets·140d★ ON YOUR LIST
Gland Pharma to Biocon: Pharma stocks rally up to 27% in a month: Can they shield portfolio from US-Iran war-led risks?AI summary· POSITIVE
- ·The Nifty Pharma index has risen by approximately 11% in the last month.
- ·The Nifty Pharma index has outperformed the Nifty 50, which saw a 3.6% decline in the same period.
- ·Year-to-date, the Nifty Pharma index has gained 9.4%, while the Nifty 50 has fallen by an equal margin.
VERIFIEDET Stocks·141d★ ON YOUR LIST
Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookAI summary· POSITIVE
- ·Gland Pharma's stock reached a 52-week high after strong March quarter and full-year financial results.
- ·The company's European subsidiary, Cenexi, is showing improved profitability.
- ·Future growth is expected from capacity expansions, new product launches, and an expanding contract development and manufacturing business.
VERIFIEDET Markets·143d★ ON YOUR LIST
Gland Pharma,6 stocks hit 52-week highs, rally up to 20% in a monthVERIFIEDET Stocks·143d★ ON YOUR LIST
Gland Pharma,6 stocks hit 52-week highs, rally up to 20% in a monthAI summary· POSITIVE
- ·Gland Pharma is among the stocks that have reached a 52-week high.
- ·Several stocks have hit their 52-week highs.
- ·These stocks have seen rallies of up to 20% in the past month.
Google News, India stocks·143d★ ON YOUR LIST
Sensex Today Ends Marginally Higher | Nifty Above 23,600 | Gland Pharma Up 15% - Equitymaster